Status:

COMPLETED

Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study

Lead Sponsor:

University of Liverpool

Collaborating Sponsors:

ViiV Healthcare

Makerere University

Conditions:

HIV

Pregnancy

Eligibility:

FEMALE

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

Aim: To evaluate dolutegravir (DTG) pharmacokinetics in pregnant HIV-infected women Rationale: In developing countries many women present with a new HIV diagnosis in late pregnancy, and are at high r...

Detailed Description

Antiretroviral therapy (ART) in pregnancy is able to effectively reduce mother-to-child transmission (MTCT) of HIV. If untreated, the risk of transmission is around 25% (greater with high viral loads)...

Eligibility Criteria

Inclusion

  • Able to provide informed consent
  • Willing to participate,
  • Women age 18 years and above
  • Pregnant
  • Untreated HIV infection in late pregnancy at ≥28 - 36 weeks gestation

Exclusion

  • Received antiretroviral drugs in previous 6 months
  • Ever received integrase inhibitors
  • Serum haemoglobin \< 8.0 g/dl
  • Elevations in serum levels of alanine aminotransferase (ALT) \>5 times the upper limit of normal (ULN) or ALT \>3xULN and bilirubin \>2xULN (with \>35% direct bilirubin)
  • eGFR \< 50ml/min
  • Active Hepatitis B infection, history or clinical suspicion of unstable liver disease, or subjects with severe liver disease (Class C by Childs-Hugh criteria)
  • Severe pre-eclampsia (e.g. HELLP), or other pregnancy related events such as renal or liver abnormalities (e.g. grade 2 or above proteinuria, elevation in serum creatinine (above 2.5 x ULN), total bilirubin ALT or AST)
  • Paternal non-consent (where disclosure to male partner has been made)
  • Clinical depression or clinical judgement suggests increased risk of suicidality

Key Trial Info

Start Date :

March 14 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 6 2018

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT02245022

Start Date

March 14 2017

End Date

December 6 2018

Last Update

September 4 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Desmond Tutu HIV Foundation

Cape Town, Western Cape, South Africa

2

Infectious Diseases Institute

Kampala, Uganda

Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study | DecenTrialz